Table 1.
Structures of the repeating units containing O-acetyl groups of bacterial polysaccharides antigens of vaccines licensed or tested in clinical trials.
| Polysaccharide | Repeat Unit |
|---|---|
| Neisseria meningitidis | |
| Group A | →6)-α-d-ManpNAc(3/4OAc)-(1→OPO3→ |
| Group C | →9)-α-d-Neu5Ac(7/8OAc)-(2→ |
| Group W | →6)-α-d-Galp-(1→4)-α-d-Neu5Ac(7/9OAc)-(2→ |
| Group Y | →6)-α-d-Glcp-(1→4)-α-d-Neu5Ac(7/9OAc)-(2→ |
| Group B Streptococcus | |
| Type Ia | →4)-[α-d-Neu5Ac(7/8/9OAc)-(2→3)-β-d-Galp-(1→4)-β-d-GlcpNAc-(1→3)]-β-d-Galp-(1→4)-β-d-Glcp-(1→ |
| Type Ib | →4)-[α-d-Neu5Ac(7/8/9OAc)-(2→3)-β-d-Galp-(1→3)-β-d-GlcpNAc-(1→3)]-β-d-Galp-(1→4)-β-d-Glcp-(1→ |
| Type II | →3)-β-d-Glcp-(1→2)-[α-d-Neu5Ac(7/8/9OAc)-(2→3)]-β-d-Galp-(1→4)-β-D-GlcpNAc-(1→3)-[β-d-Galp-(1→6)]-β-d-Galp-(1→4)-β-d-Glcp-(1→ |
| Type III | →6)-[α-d-Neu5Ac(7/8/9OAc)-(2→3)-β-d-Galp-(1→4)]-β-d-GlcpNAc-(1→3)]-β-d-Galp-(1→4)-β-d-Glcp-(1→ |
| Type V | →4)-[α-d-Neu5Ac(7/8/9OAc)-(2→3)-β-d-Galp-(1→4)-β-d-GlcpNAc-(1→6)]-α-d-Glcp-(1→4)-[β-d-Glcp-(1→3)]-β-d-Galp-(1→4)-β-d-Glcp-(1→ |
| Type VI | →6)-[α-d-Neu5Ac(7/8/9OAc)-(2→3)-β-d-Galp-(1→3)]-β-d-Glcp-(1→3)-β-d-Galp-(1→4)-β-d-Glcp-(1→ |
| Streptococcus pneumoniae | |
| Type 1 | →3)-d-AAT-α-Galp-(1→4)-α-d-GalpA(2/3OAc)-(1→3)-α-d-GalpA-(1→ |
| Type 7F | →6)-[β-d-Galp-(1→2)]-α-d-Galp-(1→3)-β-L-Rhap(2OAc)-(1→4)-β-d-Glcp-(1→3)-[α-d-GlcpNAc-(1→2)-α-L-Rhap-(1→4)]-β-d-GalpNAc-(1→ |
| Type 9V | →4)-α-d-Glcp(2/3OAc)-(1→4)-α-d-GlcpA-(1→3)-α-d-Galp-(1→3)-β-d-ManpNAc(4/6OAc)-(1→4)-β-d-Glcp-(1→ |
| Type 15B | →6)-[α-d-Galp(2/3/4/6OAc)-(1→2)-[Gro-(2→P→3)]-β-d-Galp-(1→2)]-β-d-GlcpNAc-(1→3)-β-d-Galp-(1→4)-β-d-Glcp-(1→ |
| Type 17F | →3)-β-L-Rhap-(1→4)-β-d-Glcp-(1→3)-α-d-Galp-(1→3)-β-L-Rhap(2OAc)-(1→4)-α-L-Rhap-(1→2)-d-Ara-ol-(1→P→ |
| Type 18C | →4)-β-d-Glcp-(1→4)-[α-d-Glcp(6OAc)-(1→2)][Gro-(1→P→3)]-β-d-Galp-(1→4)-α-d-Glcp-(1→3)-β-L-Rhap-(1→ |
| Type 22F | →4)-β-d-GlcpA-(1→4)-[α-d-Glcp-(1→3)]-β-L-Rhap(2OAc)-(1→4)-α-d-Glcp-(1→3)-α-d-Galf-(1→2)-α-L-Rhap-(1→ |
| Type 33F | →3)-β-d-Galp-(1→3)-[α-d-Galp-(1→2)]-α-d-Galp-(1→3)-β-d-Galf-(1→3)-β-d-Glcp-(1→5)-β-d-Galf(2OAc)-(1→ |
| Salmonella enterica | |
| typhi Vi | →)-α-d-GalpNAcA(3OAc)-(1→ |
| Staphylococcus aureus | |
| Type 5 | →4)-β-d-ManpNAcA-(1→4)-α-L-FucpNAc(3OAc)-(1→3)-β-d-FucpNAc-(1→ |
| Type 8 | →3)-β-d-ManpNAcA(4OAc)-(1→3)-α-L-FucpNAc-(1→3)-α-d-FucpNAc-(1→ |
Abbreviations: Glc, Glucose; Gal, Galactose; Neu5Ac, N-acetyl neuraminic acid (sialic acid); Rha, Rhamnose; GlcNAc, N-acetyl Glucosamine; GalNAc, N-acetyl Galactosamine; FucNAc, N-acetyl Fucosamine; ManNAcA, N-acetyl Mannuronic Acid; AAT, 2-acetamido-4-amino-2,4,6-trideoxygalactose; Gro, glycerol, Pne, 2-acetamido-2,6-dideoxytalose; Sug, 2-acetamido-2,6-deoxyhexose-4-ulose; P, phosphate in a phosphodiester linkage.